Alethia Biotherapeutics Closes Financing

Alethia Biotherapeutics Inc., a Montréal, Québec, Canada-based biotechnology company focusing on the development of therapeutic monoclonal antibodies, has closed a new financing.

Update: The investment amounts to $4.7m.


The amount was not disclosed.


Backers include AgeChem Venture Fund, BDC Venture Capital and GO Capital, as well as existing investor Cellscript.

The company intends to use the proceeds to advance its lead bone antiresorprtive candidate AB-25E9 into the studies required to submit an IND.

Created in 2002 and led by Mr. Yves Cornellier, President & CEO, and Dr. Mario Filion, CSO, Alethia develops monoclonal antibody therapeutics to novel clinically relevant targets identified using its patented STAR discovery technology. It has developed a pipeline of novel, clinically relevant therapeutic targets that included Siglec-15, a regulator of osteoclast differentiation and function.



Join the discussion